In the only other prospective study (LINC 3) of an adrenal steroidogenesis inhibitor with reliable central MRI reading, more patients had a decrease in tumor volume (38%) than had an increase (33%) with up to 48 weeks of treatment with osilodrostat, despite an approximate doubling of plasma ACTH from baseline (26). The gene discussed is POMC; the disease is neoplasm.